Cerebrospinal fluid protein dynamic driver network: At the crossroads of brain tumorigenesis.

To get a better understanding of the ongoing in situ environmental changes preceding the brain tumorigenesis, we assessed cerebrospinal fluid (CSF) proteome profile changes in a glioma rat model in which brain tumor invariably developed after a single in utero exposure to the neurocarcinogen ethylnitrosourea (ENU). Computationally, the CSF proteome profile dynamics during the tumorigenesis can be modeled as non-smooth or even abrupt state changes. Such brain tumor environment transition analysis, correlating the CSF composition changes with the development of early cellular hyperplasia, can reveal the pathogenesis process at network level during a time before the image detection of the tumors. In our controlled rat model study, matched ENU- and saline-exposed rats' CSF proteomics changes were quantified at approximately 30, 60, 90, 120, 150 days of age (P30, P60, P90, P120, P150). We applied our transition-based network entropy (TNE) method to compute the CSF proteome changes in the ENU rat model and test the hypothesis of the critical transition state prior to impending hyperplasia. Our analysis identified a dynamic driver network (DDN) of CSF proteins related with the emerging tumorigenesis progressing from the non-hyperplasia state. The DDN associated leading network CSF proteins can allow the early detection of such dynamics before the catastrophic shift to the clear clinical landmarks in gliomas. Future characterization of the critical transition state (P60) during the brain tumor progression may reveal the underlying pathophysiology to device novel therapeutics preventing tumor formation. More detailed method and information are accessible through our website at http://translationalmedicine.stanford.edu.

[1]  R. Z. Vêncio,et al.  Stromal-epithelial interactions in early neoplasia. , 2010, Cancer biomarkers : section A of Disease markers.

[2]  R. Packer,et al.  Insights into pediatric diffuse intrinsic pontine glioma through proteomic analysis of cerebrospinal fluid. , 2012, Neuro-oncology.

[3]  Ronald J. Moore,et al.  Characterization of individual mouse cerebrospinal fluid proteomes , 2014, Proteomics.

[4]  Patrick E. McSharry,et al.  Prediction of epileptic seizures: are nonlinear methods relevant? , 2003, Nature Medicine.

[5]  D. Wilkin,et al.  Neuron , 2001, Brain Research.

[6]  J. Whitin,et al.  Improving feature detection and analysis of surface‐enhanced laser desorption/ionization‐time of flight mass spectra , 2005, Proteomics.

[7]  B. Garcia,et al.  Proteomics , 2011, Journal of biomedicine & biotechnology.

[8]  J. Thiéry,et al.  The choroid plexus--cerebrospinal fluid system: undervaluated pathway of neuroendocrine signaling into the brain. , 2008, Acta neurobiologiae experimentalis.

[9]  L. Coussens,et al.  Inflammation, proteases and cancer. , 2006, European journal of cancer.

[10]  Kazuyuki Aihara,et al.  Identifying critical transitions and their leading biomolecular networks in complex diseases , 2012, Scientific Reports.

[11]  Kazuyuki Aihara,et al.  Development of a mathematical model that predicts the outcome of hormone therapy for prostate cancer. , 2010, Journal of theoretical biology.

[12]  C Thomsen,et al.  Fourier analysis of cerebrospinal fluid flow velocities: MR imaging study. The Scandinavian Flow Group. , 1990, Radiology.

[13]  Z. Hall Cancer , 1906, The Hospital.

[14]  G. G. Stokes "J." , 1890, The New Yale Book of Quotations.

[15]  Robert Gilmore,et al.  Catastrophe Theory for Scientists and Engineers , 1981 .

[16]  R. Bast,et al.  Three Biomarkers Identified from Serum Proteomic Analysis for the Detection of Early Stage Ovarian Cancer , 2004, Cancer Research.

[17]  R. Rosenfeld Nature , 2009, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[18]  Ericka Stricklin-Parker,et al.  Ann , 2005 .

[19]  K. Aihara,et al.  Early Diagnosis of Complex Diseases by Molecular Biomarkers, Network Biomarkers, and Dynamical Network Biomarkers , 2014, Medicinal research reviews.

[20]  S. Carpenter,et al.  Early-warning signals for critical transitions , 2009, Nature.

[21]  Sabrina S Wilson Radiology , 1938, Glasgow Medical Journal.

[22]  T. Jang,et al.  A distinct phenotypic change in gliomas at the time of magnetic resonance imaging detection. , 2008, Journal of neurosurgery.

[23]  Chul-Kee Park,et al.  Hearing preservation after gamma knife stereotactic radiosurgery of vestibular schwannoma , 2005, Cancer.

[24]  T. Mexia,et al.  Author ' s personal copy , 2009 .

[25]  J. Whitin,et al.  Alterations in Cerebrospinal Fluid Proteins in a Presymptomatic Primary Glioma Model , 2012, PloS one.

[26]  E. Diamandis,et al.  Prostaglandin D synthase concentration in cerebrospinal fluid and serum of patients with neurological disorders. , 1997, Prostaglandins.

[27]  D. Cao,et al.  TGF-beta signaling, tumor microenvironment and tumor progression: the butterfly effect. , 2010, Frontiers in bioscience.

[28]  H F Cserr,et al.  Role of Secretion and Bulk Flow of Brain Interstitial Fluid in Brain Volume Regulation , 1988, Annals of the New York Academy of Sciences.

[29]  C. E. SHANNON,et al.  A mathematical theory of communication , 1948, MOCO.

[30]  Kazuyuki Aihara,et al.  Detecting early-warning signals for sudden deterioration of complex diseases by dynamical network biomarkers , 2012, Scientific Reports.

[31]  G. Vachtsevanos,et al.  Epileptic Seizures May Begin Hours in Advance of Clinical Onset A Report of Five Patients , 2001, Neuron.

[32]  J. Rutka,et al.  Proteomic analyses of CSF aimed at biomarker development for pediatric brain tumors , 2014, Journal of Neuro-Oncology.

[33]  T. Jang,et al.  Aberrant nestin expression during ethylnitrosourea-(ENU)-induced neurocarcinogenesis , 2004, Neurobiology of Disease.

[34]  Thilo Gross,et al.  Early Warning Signals for Critical Transitions: A Generalized Modeling Approach , 2011, PLoS Comput. Biol..

[35]  Miss A.O. Penney (b) , 1974, The New Yale Book of Quotations.

[36]  D. Chan,et al.  Identification of tumor‐associated plasma biomarkers using proteomic techniques: From mouse to human , 2004, Proteomics.

[37]  Xiao-Ying Meng,et al.  Classification of cancer types by measuring variants of host response proteins using SELDI serum assays , 2005, International journal of cancer.

[38]  Andreas von Deimling,et al.  Identification of diagnostic serum protein profiles of glioblastoma patients , 2010, Journal of Neuro-Oncology.

[39]  T. Kotchen Prostaglandins. , 1968, JAMA.

[40]  Tilo Winkler,et al.  Self-organized patchiness in asthma as a prelude to catastrophic shifts , 2005, Nature.

[41]  Luonan Chen,et al.  Coexpression network analysis in chronic hepatitis B and C hepatic lesions reveals distinct patterns of disease progression to hepatocellular carcinoma. , 2012, Journal of molecular cell biology.

[42]  N. Rashevsky,et al.  Mathematical biology , 1961, Connecticut medicine.

[43]  Lu Tian,et al.  Cloud-based solution to identify statistically significant MS peaks differentiating sample categories , 2012, BMC Research Notes.